Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Design Therapeutics (Nasdaq: DSGN), a biotech company focused on developing treatments for serious degenerative genetic diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 19, 2024, at 12:45 p.m. ET in New York.
Investors and interested parties can access a live webcast of the fireside chat through a provided link and on the company's website at www.designtx.com in the investors section. The webcast will remain archived for at least 30 days after the presentation, allowing for later viewing.
This participation in a major healthcare conference highlights Design Therapeutics' commitment to engaging with the investment community and sharing updates on their progress in developing innovative treatments for genetic diseases.
Design Therapeutics (Nasdaq: DSGN), una azienda biotech focalizzata nello sviluppo di trattamenti per gravi malattie genetiche degenerative, ha annunciato la sua partecipazione alla Conferenza Sanitaria Globale Cantor 2024. La direzione dell'azienda prenderà parte a una chiacchierata informale giovedì, 19 settembre 2024, alle 12:45 p.m. ET a New York.
Investitori e parti interessate possono accedere a un webcast dal vivo della chiacchierata tramite un link fornito e sul sito web dell'azienda all'indirizzo www.designtx.com nella sezione investitori. Il webcast resterà archiviato per almeno 30 giorni dopo la presentazione, consentendo una visione successiva.
Questa partecipazione a una conferenza sanitaria di alto profilo evidenzia l'impegno di Design Therapeutics a interagire con la comunità degli investitori e a condividere aggiornamenti sui loro progressi nello sviluppo di trattamenti innovativi per malattie genetiche.
Design Therapeutics (Nasdaq: DSGN), una empresa biotecnológica centrada en el desarrollo de tratamientos para enfermedades genéticas degenerativas graves, ha anunciado su participación en la Conferencia Global de Salud Cantor 2024. La dirección de la empresa participará en una charla informal el jueves, 19 de septiembre de 2024, a las 12:45 p.m. ET en Nueva York.
Los inversores y partes interesadas pueden acceder a un webcast en vivo de la charla a través de un enlace proporcionado y en el sitio web de la empresa en www.designtx.com en la sección de inversores. El webcast permanecerá archivado durante al menos 30 días después de la presentación, permitiendo su visualización posterior.
Esta participación en una importante conferencia de salud subraya el compromiso de Design Therapeutics de interactuar con la comunidad inversionista y de compartir actualizaciones sobre su progreso en el desarrollo de tratamientos innovadores para enfermedades genéticas.
디자인 테라퓨틱스(나스닥: DSGN)는 심각한 퇴행성 유전 질환 치료 개발에 중점을 둔 생명공학 회사로, 2024년 칸토 글로벌 헬스케어 컨퍼런스에 참가할 것이라고 발표했습니다. 회사 경영진은 2024년 9월 19일 목요일 오후 12시 45분 ET에 뉴욕에서 비공식 대화에 참여할 예정입니다.
투자자와 관심 있는 분들은 제공된 링크를 통해 실시간 웹캐스트를 시청할 수 있으며, 회사 웹사이트 www.designtx.com의 투자자 섹션에서도 참고하실 수 있습니다. 웹캐스트는 발표 후 최소 30일 동안 아카이브되어 나중에 시청할 수 있습니다.
이 주요 의료 컨퍼런스에서의 참여는 디자인 테라퓨틱스가 투자 커뮤니티와 소통하고 유전 질환 치료 혁신 개발에 대한 진행 상황을 공유하려는 의지를 강조합니다.
Design Therapeutics (Nasdaq: DSGN), une entreprise biotechnologique axée sur le développement de traitements pour des maladies génétiques dégénératives graves, a annoncé sa participation à la Conférence Mondiale de Santé Cantor 2024. La direction de l'entreprise participera à une discussion informelle le jeudi 19 septembre 2024 à 12h45 ET à New York.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la discussion via un lien fourni et sur le site web de l'entreprise à l'adresse www.designtx.com dans la section investisseurs. Le webinaire sera archivé pendant au moins 30 jours après la présentation, permettant ainsi une vision ultérieure.
Cette participation à une conférence de santé majeure souligne l'engagement de Design Therapeutics à interagir avec la communauté des investisseurs et à partager des mises à jour sur leurs progrès dans le développement de traitements innovants pour les maladies génétiques.
Design Therapeutics (Nasdaq: DSGN), ein Biotech-Unternehmen, das sich auf die Entwicklung von Behandlungen für schwere degenerative genetische Krankheiten konzentriert, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference angekündigt. Das Management des Unternehmens wird am Donnerstag, den 19. September 2024, um 12:45 Uhr ET in New York an einem informellen Gespräch teilnehmen.
Investoren und Interessierte können über einen bereitgestellten Link auf einen live-Webcast des Gesprächs zugreifen und auf der Unternehmenswebsite www.designtx.com im Investorenbereich. Der Webcast wird mindestens 30 Tage nach der Präsentation archiviert, sodass eine spätere Ansicht möglich ist.
Die Teilnahme an einer wichtigen Gesundheitskonferenz unterstreicht das Engagement von Design Therapeutics, mit der Investoren-Community in Kontakt zu treten und Updates zu ihren Fortschritten bei der Entwicklung innovativer Behandlungen für genetische Krankheiten zu teilen.
- None.
- None.
CARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 12:45 p.m. ET in New York.
A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation.
About Design Therapeutics
Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy, Huntington’s disease and myotonic dystrophy type-1. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
When is Design Therapeutics (DSGN) participating in the 2024 Cantor Global Healthcare Conference?
How can I watch Design Therapeutics' (DSGN) fireside chat at the Cantor Global Healthcare Conference?
What is the focus of Design Therapeutics (DSGN) as a biotechnology company?
How long will the webcast of Design Therapeutics' (DSGN) fireside chat be available?
